

Product Data Sheet

Product Name: LL-K8-22

Cat. No.: GC73219

Chemical Properties

Cas. No.


Formula $C_{37}H_{43}N_5O$ M.Wt 573.77

Solubility DMSO : 125 mg/mL (217.86 mM; Storage -20°C
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μ M, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research.

LL-K8-22 (0-10 μ M, 24 h) degrades the CDK8-cyclin C complex in a dose-dependent manner[1]. LL-K8-22 (0-20 μ M, 4 days) suppresses tumor cell proliferation[1]. LL-K8-22 (0-8 μ M, 24 h) inhibits

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

CDK8-cyclin C downstream signaling[1]. LL-K8-22 significantly downregulated EAPP (E2F family binding protein)[1].LL-K8-22 dose not affect CDK8 and CCNC mRNA levels[1].

References:

[1]. Wang M, et al. Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degradar of the CDK8-Cyclin C Complex. J Med Chem. 2023 Apr 13;66(7):4932-4951.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA